Showing results (11-20 of 20) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2006
Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activitySandra J Strauss, Lenushka Maharaj, Susan Hoare, et al.Blood|November 12, 2005
Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokinesBelén Blanco, José A Pérez-Simón, Luis I Sánchez-Abarca, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trialPrimo N Lara, Mariana Koczywas, David I Quinn, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2004
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphomaOwen A O'Connor, John Wright, Craig Moskowitz, et al.Nature Medicine|May 29, 2023
Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutationBirgit Geoerger, Manuel Schiff, Virginie Penard-Lacronique, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2008
Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemiaEyal C Attar, Daniel J De Angelo, Jeffrey G Supko, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2004
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphomaAndre Goy, Anas Younes, Peter McLaughlin, et al.Blood|December 23, 2006
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomibGeorge Mulligan, Constantine Mitsiades, Barb Bryant, et al.Blood|August 11, 2007
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialPaul G Richardson, Pieter Sonneveld, Michael Schuster, et al.The New England Journal of Medicine|June 17, 2005
Bortezomib or high-dose dexamethasone for relapsed multiple myelomaPaul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.Pageof 2